Want to see EVFM full AI Analyst Report?
Evofem Biosciences (EVFM) AI Stock Analysis
Top Page
Evofem Biosciences
(Other OTC:EVFM)
The overall score is at the minimum of 37, driven primarily by a severely strained balance sheet with negative equity and insolvency risk. Declining revenues and persistent unprofitability compound these issues. While cash flow improvement and a strategic manufacturing expansion are minor positives, they are overwhelmingly overshadowed by the company's critical financial instability and near-zero stock price.
Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $795.18K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.03
- Revenue Growth
- 4.49%
- EPS Growth
- -89.40%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Evofem Biosciences Business Overview & Revenue Model
Company Description
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phex...
Evofem Biosciences Financial Statement Overview
Summary
Financial health is critically weak. The balance sheet shows negative equity of -$82.5M and total debt of $68.5M against only $7.5M in assets, indicating severe insolvency risk. While cash flow has improved to near breakeven, revenue is declining (-23.8%) and the company is unprofitable with a -100% net margin.
Income Statement
25NegativeBalance Sheet
5Very NegativeCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.05M | 20.18M | 19.36M | 18.22M | 16.84M | 8.24M |
| Gross Profit | 13.04M | 15.07M | 15.53M | 11.71M | 12.42M | 4.19M |
| EBITDA | -4.31M | 2.06M | -6.92M | -16.07M | -82.08M | -165.78M |
| Net Income | -15.30M | 391.00K | -8.86M | 52.98M | -76.70M | -205.19M |
Balance Sheet | ||||||
| Total Assets | 7.52M | 20.27M | 23.79M | 10.55M | 25.16M | 42.51M |
| Cash, Cash Equivalents and Short-Term Investments | 285.00K | 578.00K | 741.00K | 580.00K | 2.77M | 7.73M |
| Total Debt | 68.50M | 54.55M | 45.97M | 43.37M | 71.13M | 115.68M |
| Total Liabilities | 90.01M | 89.71M | 95.05M | 77.06M | 96.96M | 142.09M |
| Stockholders Equity | -82.49M | -69.44M | -71.26M | -66.51M | -71.80M | -99.58M |
Cash Flow | ||||||
| Free Cash Flow | -477.00K | -2.00M | -3.90M | -8.97M | -70.75M | -149.61M |
| Operating Cash Flow | -472.00K | -1.99M | -3.88M | -8.97M | -70.41M | -146.67M |
| Investing Cash Flow | 52.00K | -62.00K | -569.00K | -4,000 | -341.00K | -2.69M |
| Financing Cash Flow | 14.00K | 1.89M | 4.62M | 4.78M | 61.94M | 90.69M |
Evofem Biosciences Risk Analysis
Evofem Biosciences disclosed 87 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEvofem Biosciences Peers Comparison
Overall Rating
LPCN51Neutral
DARE42Neutral
PTN42Neutral- EVFM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| LPCN | 51Neutral | $11.87M | -0.77 | -64.75% | ― | -62.70% | -121.27% |
| DARE | 42Neutral | $13.76M | -0.89 | -748.08% | ― | ― | ― |
| PTN | 42Neutral | $8.90M | -0.95 | -115.00% | ― | ― | ― |
| EVFM | 37Underperform | $795.18K | -0.05 | 20.76% | ― | 4.49% | -89.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EVFM | Evofem Biosciences, Inc. | 0.01 | 0.00 | 0.00% | |
| PTN | Palatin Technologies, Inc. | 5.00 | -1.50 | -23.08% | |
| DARE | Daré Bioscience | 0.70 | -1.22 | -63.59% | |
| LPCN | Lipocine Inc | 1.44 | -1.21 | -45.66% |
Evofem Biosciences Corporate Events
Evofem Expands PHEXX Manufacturing Capacity for Global Growth
PositiveOn September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou to add them as a producer and supplier of PHEXX, its hormone-free contraceptive gel. The mov...
Evofem Biosciences Updates Investors via New Presentation
NeutralEvofem Biosciences, Inc., a biotechnology company focused on women’s health, periodically shares corporate slide presentations with the investment community at industry and other conferences.The company has posted its current slide deck to the...
Evofem Biosciences Enters New Subordinated Debt Agreement
NegativeOn July 8, 2026, Evofem Biosciences entered into a subordinated promissory note with HUB Cyber Security, Ltd. for $706,304, carrying 12% annual interest compounded monthly and maturing 11 months from that date. The deal closed the same day, and the n...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026